Clinical Trial Update: A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC [Phase 2]

View source ↗

Summary

This is a Phase II, multicenter, open-label neoadjuvant trial evaluating Inavolisib with Pertuzumab and Trastuzumab plus Nab-paclitaxel for PIK3CA-mutated, HER2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Pik3ca-mutated Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• HERCEPTIN (trastuzumab)
• Inavolisib (Inavolisib)
• Perjeta (pertuzumab)

Snippet

Sponsor: Zhimin Shao | Conditions: Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING